| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Casey Lynch last filed a Form 4 in January 2022, as Chief Executive Officer at QNCX. Casey Lynch's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 109,895 shares of QNCX. The QNCX filings lean toward selling, a net 120,000 shares.
Casey Lynch has 7 Form 4 filings on record from February 2020 to January 2022, all as Chief Executive Officer at Quince Therapeutics (QNCX), 2020–2022.
The 30 reported transactions were 25 open-market sales, 4 option or other derivative awards and 1 option exercise.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $4.4M.
The largest open-market sale was 60,000 shares of QNCX at an average $38.49 on February 3, 2021, about $2.3M.
Shares as reported in the last Form 4 for each company; the most recent is from January 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 10, 2021 | QNCX Quince Therapeutics, Inc. | Chief Executive Officer | Sell | 30,000 | $34.58 | $1,037,360.76 | -3.0% | +195.6% | -88.9% | |
| Mar 22, 2021 | QNCX Quince Therapeutics, Inc. | Chief Executive Officer | Sell | 30,000 | $35.59 | $1,067,610.75 | -2.9% | +56.0% | -82.9% | |
| Feb 3, 2021 | QNCX Quince Therapeutics, Inc. | Chief Executive Officer | Sell | 60,000 | $38.49 | $2,309,599.92 | -5.5% | - | - |